Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of AV608 in idiopathic detrusor overactivity
2005-005868-93Phase 2Completed
- Sponsor
- Avera Pharmaceuticals
- Start
- Mar 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic detrusor overactivity (IDO) and overactive bladder (OAB) comparing AV608 with Placebo (2 arms). Primary endpoint: Change in maximum cystometric bladder capacity. Started Mar 2006; status: completed.
02
Drugs
AV608
03
Conditions
idiopathic detrusor overactivity (IDO)overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-005868-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005868-93.